Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 7/20 | 0.56 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.54 |
| ▸ | GLP1R | P43220 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP4 | P49662 | 1/20 | 0.49 |
| ▸ | CASP5 | P51878 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362779 | 0.97 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30543189 | 0.97 | VIPR2 (0.53) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29425538 | 0.95 | VIPR2 (0.51) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29462368 | 0.93 | VIPR2 (0.50) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29466598 | 0.90 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29520980 | 0.89 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL29778027 | 0.89 | VIPR2 (0.54) | VIPR2VIPR1F2BACE1BACE2 | |
| SCHEMBL30622615 | 0.89 | BACE1 (0.58) | F2BACE1BACE2CASP1CASP3 | |
| SCHEMBL30798736 | 0.88 | F2 (0.53) | VIPR2VIPR1F2CASP1CASP3 | |
| SCHEMBL30168728 | 0.87 | TFPI (0.58) | VIPR2VIPR1F2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024504-A1 | SITE-SELECTIVE LYSINE ACETYLATION OF HUMAN IMMUNOGLOBULIN G AND IgG-RELATED PRODUCTS FOR IMMUNOTHERAPY | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024504-A1 | SITE-SELECTIVE LYSINE ACETYLATION OF HUMAN IMMUNOGLOBULIN G AND IgG-RELATED PRODUCTS FOR IMMUNOTHERAPY | FCGR3B, FCGR2A, FCGR1A | VIPR2 3552/4885VIPR1 3426/4885F2 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.